128 Participants Needed

Bupivacaine Injection for Postoperative Pain in Breast Reduction

Recruiting at 1 trial location
LC
CH
Overseen ByChristopher Hughes, MD, MPH
Age: < 65
Sex: Any
Trial Phase: Phase 4
Sponsor: Connecticut Children's Medical Center
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are already taking narcotics at the time of surgery.

What data supports the effectiveness of the drug Marcaine (Bupivacaine) for reducing postoperative pain in breast reduction surgery?

Research shows that using bupivacaine (Marcaine) during breast reduction surgery can significantly reduce postoperative pain and the need for additional pain medication. In one study, patients who received bupivacaine reported better pain relief compared to those who received saline, and they required less opioid medication after surgery.12345

Is bupivacaine safe for use in humans?

Bupivacaine has been used safely in various surgical procedures, including breast surgeries and knee replacements, without apparent adverse reactions. It is generally considered safe for managing postoperative pain in humans.13567

How does the drug saline differ from other treatments for postoperative pain in breast reduction?

Saline, when used for postoperative pain in breast reduction, serves as a control treatment and does not provide the same pain relief as bupivacaine, a local anesthetic that significantly reduces pain and the need for additional pain medication.12389

What is the purpose of this trial?

The main question this randomized control trial aims to answer is:• Is the use of intraoperative subpectoral bupivacaine associated with decreased post-operative pain in adolescent patients who undergo bilateral reduction mammaplastyParticipants will be randomized into the study group that intraoperatively receives 30cc of subpectoral bupivacaine injections or into the control group that intraoperatively receives 30cc of injectable saline subpectorally. All participants will keep a pain log and pain medication log at home for the first week following surgery.Researchers will compare to see if patients who receive subpectoral bupivacaine have lower pain scores in the PACU, and lower use of narcotics post-operatively when compared to the control group who receive injectable saline.

Research Team

CH

Christopher Hughes, MD, MPH

Principal Investigator

Connecticut Children's

Eligibility Criteria

This trial is for female adolescents aged 13-21 undergoing breast reduction surgery at Connecticut Children's. They must be able to have a parent or guardian consent to the study. Excluded are those with substance use disorders, chronic pain managed by specialists, pre-surgery narcotic use, liver/kidney dysfunction, bupivacaine allergy, pregnancy, inability to report pain reliably, significant post-op complications or lost follow-up.

Inclusion Criteria

Ability of child's parent/legal guardian to understand and the willingness to sign a written informed consent document
I am having a breast reduction surgery at Connecticut Children's between 2022 and 2025.
I am female.
See 1 more

Exclusion Criteria

You have difficulty speaking or understanding and may not be able to accurately tell us if you are in pain.
I have a history of substance use disorder or chronic pain managed by a specialist.
I must see my doctor within 1 and 4 weeks after surgery.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants undergo bilateral reduction mammaplasty with either subpectoral bupivacaine or saline injections

Day of surgery
1 visit (in-person)

Post-operative Monitoring

Participants record daily pain scores and medication use in a home log for the first week following surgery

1 week
Home-based monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment, including pain score and narcotic use assessment

4 weeks
2 visits (in-person) at 1 and 4 weeks post-op

Treatment Details

Interventions

  • Marcaine 0.25 % Injectable Solution
  • Saline
Trial Overview The study tests if injecting bupivacaine (a numbing medication) under the chest muscle during surgery reduces post-operative pain and narcotic use compared to saline (saltwater solution). Participants will be randomly assigned to receive either bupivacaine or saline and will track their pain and medication usage for one week after surgery.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Study Group 1 - InterventionExperimental Treatment1 Intervention
Participants in this group will receive 20cc of subpectoral bupivacaine injected into the fascia
Group II: Study Group 2 - ControlPlacebo Group1 Intervention
Participants in this group will receive 20cc of subpectoral saline injected into the fascia

Saline is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Normal Saline for:
  • General wound care
  • Eye irrigation
  • Skin cleansing
🇪🇺
Approved in European Union as Sodium Chloride Solution for:
  • Wound cleaning
  • Eye washing
  • Skin disinfection
🇨🇦
Approved in Canada as Physiological Saline for:
  • Wound irrigation
  • Eye flushing
  • General medical use

Find a Clinic Near You

Who Is Running the Clinical Trial?

Connecticut Children's Medical Center

Lead Sponsor

Trials
76
Recruited
30,000+

Findings from Research

In a study of 27 women undergoing reduction mammaplasty, postoperative injections of bupivacaine significantly reduced the need for morphine, with patients receiving bupivacaine consuming much less morphine compared to those receiving saline.
The effectiveness of bupivacaine in lowering morphine consumption was consistent regardless of whether it was injected into the incision margin or deep into the wound, indicating its analgesic effect is robust across different administration sites.
Intermittent injection of bupivacaine into the margin or the cavity after reduction mammaplasty.Holmgren, RT., Tarpila, E.[2019]
In a study of 37 patients undergoing breast reduction surgery, the use of the long-acting local anesthetic bupivacaine (Sensorcaine) significantly reduced the time to discharge from the postanesthesia care unit, averaging 2.9 hours compared to 3.8 hours for the placebo group.
Patients who received Sensorcaine reported lower pain levels and required significantly less narcotic medication post-surgery, taking an average of 3.5 tablets compared to 6.4 tablets in the control group, indicating its efficacy in managing postoperative pain.
Intraoperative Sensorcaine significantly improves postoperative pain management in outpatient reduction mammaplasty.Culliford, AT., Spector, JA., Flores, RL., et al.[2021]
In a study of 19 women undergoing excision biopsy for benign breast lumps, bupivacaine infiltration provided complete postoperative pain relief for 14 participants, demonstrating its efficacy in pain management.
The control group, which received saline instead of bupivacaine, required significantly more opioid analgesia and still experienced inadequate pain relief, highlighting the superior effectiveness of bupivacaine without any reported adverse reactions.
Analgesia by wound infiltration after surgical excision of benign breast lumps.Owen, H., Galloway, DJ., Mitchell, KG.[2018]

References

Intermittent injection of bupivacaine into the margin or the cavity after reduction mammaplasty. [2019]
Intraoperative Sensorcaine significantly improves postoperative pain management in outpatient reduction mammaplasty. [2021]
Analgesia by wound infiltration after surgical excision of benign breast lumps. [2018]
A local anesthetic pump reduces postoperative pain and narcotic and antiemetic use in breast reconstruction surgery: a randomized controlled trial. [2021]
Abdominal wound perfusion for the relief of postoperative pain. [2019]
Intrathecal normal saline without preservative does not have a local anesthetic effect. [2021]
Bupivacaine bolus injection versus placebo for pain management following total knee arthroplasty. [2022]
Bupivacaine infiltration of the mesosalpinx in ambulatory surgical laparoscopic tubal sterilization. [2018]
Decreased postoperative pain, narcotic, and antiemetic use after breast reduction using a local anesthetic pain pump. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security